ReviewJournal of neurology1999
Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration.
Review in Journal of neurology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 132 citations in OpenAlex.
- Prognostic factors of survival in corticobasal syndrome and corticobasal degeneration: A scoping review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Dementia in Progressive Supranuclear Palsy: A Narrative Review.Neurology and therapy · 2026Review
- Revisiting the 2015 MDS diagnostic criteria for Parkinson disease: insights from autopsy-confirmed cases.NPJ Parkinson's disease · 2025Article
- Clinical Spectrum of Tauopathies.Frontiers in neurology · 2022Review
- Review
- Four-Repeat Tauopathies: Current Management and Future Treatments.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Review
- PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers.Frontiers in neurology · 2020Article
- Article
- Sensitivity and Specificity of the ECAS in Parkinson's Disease and Progressive Supranuclear Palsy.Parkinson's disease · 2018Article
- Myoclonic Disorders.Brain sciences · 2017Review
- An autopsy-confirmed case of progressive supranuclear palsy with predominant postural instability.Acta neuropathologica communications · 2016Article
- Article
- Abnormal Echogenicity of the Substantia Nigra, Raphe Nuclei, and Third-Ventricle Width as Markers of Cognitive Impairment in Parkinsonian Disorders: A Cross-Sectional Study.Parkinson's disease · 2016Article
- Changes in the thalamus in atypical parkinsonism detected using shape analysis and diffusion tensor imaging.AJNR. American journal of neuroradiology · 2014Article
- Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias.Alzheimer's research & therapy · 2014Review
- Spatial patterns of the tau pathology in progressive supranuclear palsy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2013Article
- Visual hallucinations in the differential diagnosis of parkinsonism.Journal of neurology, neurosurgery, and psychiatry · 2012Review
- Phenotypic variation of autosomal-dominant corticobasal degeneration.European neurology · 2012Article
- What are the different initial presentations of frontotemporal dementia?Journal of molecular neuroscience : MN · 2011Article
- Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome.Brain : a journal of neurology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progressive supranuclear palsy (PSP) and cortocobasal degeneration (CBD) are often clinically confused with each other because they share a rapid disease progression, parkinsonism that responds poorly or transiently to levodopa therapy, and associated signs (e.g., ocular abnormalities, pyramidal signs and cognitive involvement). To improve the accuracy in diagnosing these disorders, this study examined the clinical features of 51 patients pathologically diagnosed with PSP and CBD. Logistic regression analysis identified two sets of predictors (models) for CBD patients, one consisting of asymmetric parkinsonism, cognitive disturbances at onset and instability and falls at first clinic visit, and the other one of asymmetric parkinsonism, cognitive disturbances at symptom onset and speech disturbances. While PSP patients often had severe postural instability at onset, symmetric parkinsonism, vertical supranuclear gaze palsy, speech and frontal lobe-type features, CBD patients presented with lateralized motor (e.g., parkinsonism, dystonia or myoclonus) and cognitive signs (e.g., ideomotor apraxia, aphasia or alien limb). On the other hand, CBD patients presenting with an alternate phenotype characterized by early severe frontal dementia and bilateral parkinsonism were generally misdiagnosed. PSP patients without vertical supranuclear gaze palsy were misdiagnosed. Recognizing the features which differentiate these disorders and the less obvious disease presentations as well as developing an increased index of suspicion will improve the diagnostic accuracy of these disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.